• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.大麻二酚在革新阿片类药物使用障碍管理方面的治疗潜力。
Cureus. 2023 Dec 16;15(12):e50634. doi: 10.7759/cureus.50634. eCollection 2023 Dec.
2
Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.辅助使用非阿片类药物大麻二酚治疗阿片类药物戒断。
Cannabis Cannabinoid Res. 2022 Oct;7(5):569-581. doi: 10.1089/can.2021.0089. Epub 2021 Oct 22.
3
Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder.阿片类药物使用障碍治疗人群中对大麻二酚的使用和认知。
Harm Reduct J. 2024 Jul 17;21(1):135. doi: 10.1186/s12954-024-01051-5.
4
Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.大麻二酚对接受丁丙诺啡治疗的阿片类物质使用障碍患者线索诱导性渴求的影响:一项小型概念验证性开放标签研究。
Integr Med Rep. 2022 Aug 1;1(1):157-163. doi: 10.1089/imr.2022.0070. Epub 2022 Aug 26.
5
Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.医院环境中阿片类药物戒断的管理和阿片类药物使用障碍药物的启用。
Hosp Pract (1995). 2022 Oct;50(4):251-258. doi: 10.1080/21548331.2022.2102776. Epub 2022 Jul 22.
6
Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.大麻二酚对阿片类物质使用障碍患者奖赏及应激相关神经认知过程的影响:一项先导性、双盲、安慰剂对照、随机交叉试验。
Front Psychiatry. 2023 Mar 30;14:1155984. doi: 10.3389/fpsyt.2023.1155984. eCollection 2023.
7
Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care.需要重症监护的阿片类药物使用障碍患者的疼痛管理考量
J Clin Pharmacol. 2022 Apr;62(4):449-462. doi: 10.1002/jcph.1999. Epub 2022 Jan 5.
8
Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.大麻二酚作为成瘾治疗药物开发的早期阶段:阿片类药物复发占据首要位置。
Neurotherapeutics. 2015 Oct;12(4):807-15. doi: 10.1007/s13311-015-0373-7.
9
The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder.药用大麻作为阿片类物质使用障碍新兴疗法的作用。
Pain Ther. 2024 Jun;13(3):435-455. doi: 10.1007/s40122-024-00599-1. Epub 2024 Apr 27.
10
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence.大麻二酚(CBD)在慢性疼痛管理中的作用:对现有证据的评估。
Curr Pain Headache Rep. 2020 Jan 24;24(2):4. doi: 10.1007/s11916-020-0835-4.

本文引用的文献

1
Editorial: Opioid overdose and harm reduction approaches to combat the looming crisis.社论:阿片类药物过量及减少伤害的方法以应对迫在眉睫的危机
Front Psychiatry. 2023 Apr 20;14:1197388. doi: 10.3389/fpsyt.2023.1197388. eCollection 2023.
2
Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial.大麻二酚对阿片类物质使用障碍患者奖赏及应激相关神经认知过程的影响:一项先导性、双盲、安慰剂对照、随机交叉试验。
Front Psychiatry. 2023 Mar 30;14:1155984. doi: 10.3389/fpsyt.2023.1155984. eCollection 2023.
3
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.大麻使用对阿片类激动剂治疗结果的影响差异:来自 OPTIMA 研究的探索性分析。
J Subst Use Addict Treat. 2023 Jun;149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30.
4
Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach.利用大麻素治疗物质使用障碍的人体研究证据:一种系统方法的范围综述。
Int J Environ Res Public Health. 2023 Feb 24;20(5):4087. doi: 10.3390/ijerph20054087.
5
Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review.阿片类药物成瘾的历史路径、传统及替代治疗方案(包括氯胺酮、大麻素和去甲诺勃卡因)的戒断:一项叙述性综述
Health Psychol Res. 2022 Oct 7;10(4):38672. doi: 10.52965/001c.38672. eCollection 2022.
6
Cannabidiol Reduced the Severity of Gastrointestinal Symptoms of Opioid Withdrawal in Male and Female Mice.大麻二酚减轻了雄性和雌性小鼠阿片类药物戒断引起的胃肠道症状的严重程度。
Cannabis Cannabinoid Res. 2024 Apr;9(2):547-560. doi: 10.1089/can.2022.0036. Epub 2022 Dec 27.
7
Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study.大麻二酚对接受丁丙诺啡治疗的阿片类物质使用障碍患者线索诱导性渴求的影响:一项小型概念验证性开放标签研究。
Integr Med Rep. 2022 Aug 1;1(1):157-163. doi: 10.1089/imr.2022.0070. Epub 2022 Aug 26.
8
Public Health Implications of Cannabis Legalization: An Exploration of Adolescent Use and Evidence-Based Interventions.大麻合法化对公共卫生的影响:青少年使用情况及循证干预措施探究
Int J Environ Res Public Health. 2022 Mar 11;19(6):3336. doi: 10.3390/ijerph19063336.
9
Biomarkers of the Endocannabinoid System in Substance Use Disorders.物质使用障碍的内源性大麻素系统生物标志物。
Biomolecules. 2022 Mar 3;12(3):396. doi: 10.3390/biom12030396.
10
"I got a bunch of weed to help me through the withdrawals": Naturalistic cannabis use reported in online opioid and opioid recovery community discussion forums.“我抽了很多大麻来帮助我度过戒断期”:在网上阿片类药物和阿片类药物康复社区讨论论坛上报告了自然主义大麻使用情况。
PLoS One. 2022 Feb 8;17(2):e0263583. doi: 10.1371/journal.pone.0263583. eCollection 2022.

大麻二酚在革新阿片类药物使用障碍管理方面的治疗潜力。

The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.

作者信息

Le Kelvin, Au Joanne, Hua Jean, Le Khang Duy Ricky

机构信息

Melbourne Medical School, The University of Melbourne, Melbourne, AUS.

Department of Anaesthesia & Pain Management, The Royal Melbourne Hospital, Melbourne, AUS.

出版信息

Cureus. 2023 Dec 16;15(12):e50634. doi: 10.7759/cureus.50634. eCollection 2023 Dec.

DOI:10.7759/cureus.50634
PMID:38226097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10789504/
Abstract

Opioid use disorder (OUD) is a significant cause of morbidity and mortality worldwide and is linked to a complex interplay of biopsychosocial factors as well as the increasing overprescription and availability of opioid medications. Current OUD management relies on the controlled provision of opioid medications, such as methadone or buprenorphine, known as opioid replacement therapy. There is variable evidence regarding the long-term efficacy of these medications in improving the management of OUD, thereby necessitating an exploration into innovative approaches to complement, or even take the place of, existing treatment paradigms. Cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, has garnered attention for its diverse pharmacological properties, including anti-inflammatory, analgesic, and anxiolytic effects. Preliminary studies suggest that CBD may target opioid withdrawal pathways that make CBD a potential therapeutic option for OUD. This narrative review synthesises current literature surrounding OUD and offers a nuanced review of the current and future role of CBD in managing this condition. In doing so, we highlight the potential avenues to explore with respect to CBD research for the guidance and development of further research opportunities, framework and policy development, and clinical considerations before medicinal CBD can be integrated into evidence-based clinical guidelines.

摘要

阿片类物质使用障碍(OUD)是全球发病和死亡的重要原因,与生物心理社会因素的复杂相互作用以及阿片类药物的过度处方和可得性增加有关。目前对OUD的管理依赖于对阿片类药物(如美沙酮或丁丙诺啡)的控制性供应,即所谓的阿片类药物替代疗法。关于这些药物在改善OUD管理方面的长期疗效,证据不一,因此有必要探索创新方法来补充甚至取代现有的治疗模式。大麻二酚(CBD)是一种从大麻植物中提取的无精神活性化合物,因其多样的药理特性(包括抗炎、镇痛和抗焦虑作用)而受到关注。初步研究表明,CBD可能作用于阿片类物质戒断途径,这使CBD成为OUD的一种潜在治疗选择。这篇叙述性综述综合了围绕OUD的现有文献,并对CBD在管理这种疾病中的当前和未来作用进行了细致入微的综述。在此过程中,我们强调了在将药用CBD纳入循证临床指南之前,在CBD研究方面需要探索的潜在途径,以指导和开发进一步的研究机会、框架和政策制定以及临床考量。